Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have biopsy proven metastatic NSCLC (Stage IV).~2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved stable disease or a partial response.~3. Patients receiving first-line erlotinib, crizotinib for EGFR mutant-positive or EML4-ALK positive NSCLC will be excluded.~4. Age ≥ 18 years~5. Patients must have measurable disease at baseline.~6. Patients can have up to only 6 discrete active extracranial lesions (≤3 in the liver and ≤3 in the lung) identified by diagnostic CT or PET/CT scan or MRI within 8 weeks prior to the initiation of SBRT.~   1. For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months~  2. Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months.~  3. Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply (section 4.3.2).~  4. Up to 2 contiguous vertebral metastases will be considered a single site of disease.~7. Patients must have a KPS \>60~8. AST, ALT \& Alkaline phosphates must be ≤ 2.5X the upper limit of normal. Total bilirubin must be within the limit of normal.~9. Patients should have adequate bone marrow function as defined by peripheral granulocyte count of ≥1500/mm³.~10. Patients should have adequate renal function (serum creatinine ≤1.5 times the ULN).~11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~    11.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:~   * Has not undergone a hysterectomy or bilateral oophorectomy; or~   * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).~12. Patients who would be receiving SBRT for lung tumors who are known or suspected by the treating radiation oncologist to have compromised lung function must have a documented forced expiratory volume in 1 second (FEV1) ≥ 1L.~13. Patients must provide verbal and written informed consent to participate in the study.~Exclusion Criteria:~1. Patients who previously received radiotherapy to the primary site with CT evidence of disease progression at the primary site within 3 months following the initial radiotherapy.~2. Patients with untreated brain metastases Patients with serious, uncontrolled, concurrent infection(s).~3. Significant weight loss (\>10%) in the prior 3 months.~4. Because the tolerance dose of SBRT to the gastrointestinal tract is not established, patients with metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes will not be eligible.~5. Patients with cutaneous metastasis of NSCLC.~6. Patients with more than 6 discrete extra-cranial lesions.~7. Participation in any investigational drug study within 4 weeks preceding the start of study treatment.~8. Unwillingness to participate or inability to comply with the protocol for the duration of the study.~9. Patients who are pregnant. Patients with reproductive capability will need to use adequate contraception during the time of participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Maintenance chemotherapy (Type: ACTIVE_COMPARATOR): FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
- Stereotactic Body Radiation Therapy (Type: EXPERIMENTAL): consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).